Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 26Recruiting 24Completed 24Active not recruiting 13Unknown 4Not yet recruiting 2Withdrawn 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 50Gynecologic 8Gastrointestinal 6Thoracic 5Head & Neck 3Genitourinary 3Sarcoma 2CNS 2Other solid neoplasm 1Other 1Dermatologic 1

Conditions

Melanoma 109Lymphoma, T-Cell, Cutaneous 27Mycosis Fungoides 22Skin Neoplasms 20Sezary Syndrome 19Lymphoma, Non-Hodgkin 16Lymphoma, Follicular 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neoplasm Metastasis 13Lymphoma, Mantle-Cell 13Lymphoma, Large-Cell, Immunoblastic 13Lymphoma, Large-Cell, Anaplastic 13Lymphoma, Large B-Cell, Diffuse 13Lymphoma, B-Cell, Marginal Zone 13Lymphoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Burkitt Lymphoma 13Hodgkin Disease 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Immunoblastic Lymphadenopathy 11Waldenstrom Macroglobulinemia 10Keratosis, Actinic 10Breast Neoplasms 10Uveal Melanoma 9Lymphoma, Extranodal NK-T-Cell 9Leukemia, Myeloid, Acute 9Leukemia, Hairy Cell 9Intraocular Lymphoma 9Carcinoma, Basal Cell 9Neoplasms 8

Interventions

glembatumumab vedotin 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1CR011-vcMMAE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Triple Negative Breast Neoplasms × Dermatologic × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡